NCT07333287

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (estimated)
• Sponsor: Shandong Provincial Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of arterial infusion chemotherapy and embolization combined with iparplidutol-volerilis (QL1706) as first-line treatment for pancreatic cancer liver metastases based on progression-free survival (PFS).

Conditions

• Pancreatic Cancer Liver Metastases
• Immunotherapy-naive

Interventions

Type	Name	Description
PROCEDURE	Interventional	Pancreatic tumor and liver metastases: TAC Liver metastases: For non-diffuse liver metastases with good blood supply: TACE
DRUG	Targeted Therapy (anti-VEGF)	Apatinib 250 mg qd
DRUG	Immunotherapy + Targeted Therapy	After 1-2 weeks Iparomlimab and Tuvonralimab (50 mg/2 mL) combined with Apatinib 250 mg qd
DRUG	Immunotherapy + Targeted Therapy + Chemotherapy	After 3 weeks Iparomlimab and Tuvonralimab (50 mg/2 mL) on day 1 Albumin-bound paclitaxel 125 mg/m² on days 2 and 9 Gemcitabine 1000 mg/m² on days 2 and 9 Apatinib 250 mg qd
OTHER	This cycle is repeated every 21 days.	Interventional therapy is discontinued if imaging shows no enhancement of tumor vessels and is resumed only upon disease progression or until intolerable adverse reactions occur.

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-02-28
• Completion: 2028-11-30
• First posted: 2026-01-12
• Last updated: 2026-01-12